

Pursuant to article 228 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October and to article 17 of Regulation (EU) n°596/2014 on market abuse, Pharma Mar, S.A. (“**Pharma Mar**” or the “**Company**”) hereby discloses the following

REGULATORY ANNOUNCEMENT

Following the regulatory announcements published on 17 May 2017 and 18 May 2017 under registry numbers 252,144 and 252,207, respectively, the Company informs that the public deed relating to the share capital increase of the Company, by means of monetary contributions and with exclusion of the pre-emptive rights, for a total amount of €2,110,900 (22,220€ of nominal amount and €2,088,680 of share premium) through the issue of 444,400 new ordinary shares, of €0.05 nominal amount each, fully subscribed by Specialised Therapeutics Investments Pty LTD ATF The Specialised Therapeutics Unit Trust, entity controlled by Specialised Therapeutics Asia Pte Ltd (the “**New Shares**”), has been duly registered with the Commercial Registry of Madrid.

Consequently, the share capital of Pharma Mar has been set at €11,132,464.35, divided into 222,649,287 shares, of €0.05 nominal amount each, all of them belonging to a single class and series.

The Company expects that the New Shares will be admitted to trading in the following days once all the requirements for the admission to trading have been met with the CNMV, the Stock Exchanges and Iberclear.

In Colmenar Viejo (Madrid), on 26 May 2017